CytoSorbents releases investor presentation on blood purification devices for ICU, cardiac surgery use

The DoD-backed HEMODEFEND-BGA program was cited with $16 million in funding, targeting a “universal plasma” approach; the program is preclinical ahead of human trials.

CytoSorb remains CE-marked in Europe, with more than 300,000 treatments across 70-plus countries; it is not cleared in the U.S. or Canada.

DrugSorb-ATR is positioned as the key North America catalyst, with two FDA Breakthrough Device designations; the device remains investigational.

CytoSorbents highlighted trailing 12-month sales of $37.3 million through June 30, 2026, with 72% gross margins.

Management flagged Q2 2026 operating cash burn of about $200K, excluding restructuring costs, with cash flow breakeven targeted in H2 2026.